Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial 
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Revenue
- Valuation
- Analyst Ratings
Upturn AI SWOT - About
BRKR 
Bruker Corporation (BRKR)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
04/22/2025: BRKR (1-star) is currently NOT-A-BUY. Pass it for now.
Upturn Star Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
Number of Analysts
14 Analysts rated it
Moderately tracked stock, growing coverage, gaining market and investor attention.
1 Year Target Price $53.95
1 Year Target Price $53.95
| 5 | Strong Buy |
| 2 | Buy |
| 7 | Hold |
| 0 | Sell |
| 0 | Strong Sell |
Analysis of Past Performance
Type Stock | Historic Profit 18.96% | Avg. Invested days 49 | Today’s Advisory PASS |
Upturn Star Rating | Upturn Advisory Performance  2.0 | Stock Returns Performance  2.0 |
| Profits based on simulation | Last Close 04/22/2025 |
Key Highlights
Company Size Mid-Cap Stock | Market Capitalization 6.33B USD | Price to earnings Ratio 80.78 | 1Y Target Price 53.95 |
Price to earnings Ratio 80.78 | 1Y Target Price 53.95 | ||
Volume (30-day avg) 14 | Beta 1.16 | 52 Weeks Range 34.06 - 72.70 | Updated Date 07/1/2025 |
52 Weeks Range 34.06 - 72.70 | Updated Date 07/1/2025 | ||
Dividends yield (FY) 0.48% | Basic EPS (TTM) 0.51 |
Analyzing Revenue: Products, Geography and Growth
Revenue by Products
Product revenue - Year on Year
Revenue by Geography
Geography revenue - Year on Year
Earnings Date
Report Date - | When - | Estimate - | Actual - |
Profitability
Profit Margin 2.31% | Operating Margin (TTM) 8.62% |
Management Effectiveness
Return on Assets (TTM) 4.79% | Return on Equity (TTM) 4.76% |
Valuation
Trailing PE 80.78 | Forward PE 18.02 | Enterprise Value 8174225601 | Price to Sales(TTM) 1.84 |
Enterprise Value 8174225601 | Price to Sales(TTM) 1.84 | ||
Enterprise Value to Revenue 2.37 | Enterprise Value to EBITDA 19.65 | Shares Outstanding 151532000 | Shares Floating 103000712 |
Shares Outstanding 151532000 | Shares Floating 103000712 | ||
Percent Insiders 31.97 | Percent Institutions 82.12 |
Analyst Ratings
Rating 3 | Target Price 53.95 | Buy 2 | Strong Buy 5 |
Buy 2 | Strong Buy 5 | ||
Hold 7 | Sell - | Strong Sell - | |
Strong Sell - |
Upturn AI SWOT
Bruker Corporation
Company Overview
History and Background
Bruker Corporation was founded in 1960 by Gu00fcnther Laukien. Initially focused on nuclear magnetic resonance (NMR) spectroscopy, it has grown through innovation and acquisitions to become a leading provider of scientific instruments and solutions.
Core Business Areas
- Bruker BioSpin Group: Designs, manufactures, and sells NMR, EPR, and preclinical MRI systems for life science, pharmaceutical, and materials research.
- Bruker CALID Group: Offers mass spectrometry and chromatography systems for various applications, including proteomics, metabolomics, food safety, and environmental analysis.
- Bruker AXS Group: Develops and manufactures X-ray diffraction and elemental analysis systems for materials research, industrial quality control, and structural biology.
- Bruker NANO Group: Provides atomic force microscopy (AFM), stylus and optical metrology, and tribology & mechanical testing instruments for nanoscale analysis and materials characterization.
Leadership and Structure
Frank H. Laukien serves as the Chairman, President, and CEO. The company operates with a decentralized structure organized around its various business segments, each with its own leadership team.
Top Products and Market Share
Key Offerings
- NMR Spectrometers: Nuclear Magnetic Resonance (NMR) spectrometers are used to determine the structure and dynamics of molecules. Bruker is a leader in the NMR market. Revenue is not directly reported but is a significant portion of BioSpin revenues. Competitors include Thermo Fisher Scientific (TMO) and JEOL.
- Mass Spectrometers: Mass spectrometers are used to identify and quantify molecules in a sample. Bruker's MALDI-TOF and timsTOF systems are popular in proteomics and other fields. Revenue is not directly reported but is a significant portion of CALID revenues. Competitors include Thermo Fisher Scientific (TMO) and Agilent Technologies (A).
- X-ray Diffraction Systems: X-ray Diffraction (XRD) systems are used to determine the crystal structure of materials. Revenue is not directly reported but is a significant portion of AXS revenues. Competitors include Rigaku and PANalytical.
- Atomic Force Microscopes: Atomic Force Microscopes are used to image materials at the nanoscale. Revenue is not directly reported but is a significant portion of NANO revenues. Competitors include Keysight Technologies (KEYS) and Park Systems.
Market Dynamics
Industry Overview
The scientific instruments industry is driven by research and development spending in academia, government, and industry. Key trends include increasing demand for analytical instruments in life sciences, materials science, and environmental monitoring.
Positioning
Bruker Corporation is a leading player in the scientific instruments market, with a strong reputation for innovation and high-quality products. Its competitive advantage lies in its broad product portfolio and technological expertise.
Total Addressable Market (TAM)
The total addressable market for scientific instruments is estimated to be tens of billions of dollars annually. Bruker is positioned to capture a significant share of this market through its diverse product offerings and strong brand recognition.
Upturn SWOT Analysis
Strengths
- Strong brand reputation
- Diverse product portfolio
- Technological leadership
- Global presence
- Recurring revenue streams from service and consumables
Weaknesses
- High R&D costs
- Dependence on research funding
- Vulnerability to economic cycles
- Complexity of product lines
Opportunities
- Growth in emerging markets
- Increasing demand for analytical instruments in life sciences
- Development of new applications for existing technologies
- Strategic acquisitions to expand product portfolio
Threats
- Intense competition
- Technological obsolescence
- Economic downturns
- Changes in government regulations
Competitors and Market Share
Key Competitors
- TMO
- A
- KEYS
- WAT
Competitive Landscape
Bruker is a strong competitor in the scientific instruments market, with a broad product portfolio and a reputation for innovation. However, it faces intense competition from larger players such as Thermo Fisher Scientific and Agilent Technologies.
Major Acquisitions
Protea Biosciences
- Year: 2020
- Acquisition Price (USD millions): 34
- Strategic Rationale: Expanded Bruker's MALDI imaging capabilities and position in spatial biology.
Growth Trajectory and Initiatives
Historical Growth: Bruker has experienced consistent growth over the past decade, driven by organic growth and acquisitions.
Future Projections: Analysts predict continued growth for Bruker, driven by demand for its products and services in life sciences and materials science.
Recent Initiatives: Recent initiatives include expanding its product portfolio through acquisitions and investing in research and development of new technologies.
Summary
Bruker Corporation is a well-established player in the scientific instruments industry with a diverse portfolio and strong reputation. It is financially stable and focused on future innovation and growth. Competition is strong, but Bruker's technology and global reach position it well. Economic fluctuations in government and academic research are primary risks.
Peer Comparison
Sources and Disclaimers
Data Sources:
- Bruker Corporation Investor Relations
- SEC Filings
- Industry Reports
- Analyst Estimates
Disclaimers:
This analysis is for informational purposes only and should not be considered investment advice. Market data is subject to change. Financial data based on best estimates with access to current quarterly reports.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About Bruker Corporation
Exchange NASDAQ | Headquaters Billerica, MA, United States | ||
IPO Launch date 2000-08-04 | Chairman, CEO & President Dr. Frank H. Laukien Ph.D. | ||
Sector Healthcare | Industry Medical Devices | Full time employees 11396 | Website https://www.bruker.com |
Full time employees 11396 | Website https://www.bruker.com | ||
Bruker Corporation, together with its subsidiaries, develops, manufactures, and distributes scientific instruments, and analytical and diagnostic solutions in the United States, Europe, the Asia Pacific, and internationally. The company operates through four segments: Bruker Scientific Instruments (BSI) BioSpin, BSI CALID, BSI Nano, and Bruker Energy & Supercon Technologies. It offers magnetic resonance spectroscop, preclinical imaging, biopharma and applied, services and lifecycle support, integrated data solution, and automation; life science tools, and single and multiple modality systems; life science mass spectrometry; MALDI Biotyper platform for bacterial and fungal identification and establish, DNA test strips, and; genotype and fluorotype molecular diagnostics kits; and research, analytical, and process analysis instruments and solutions. It provides range of portable analytical and bioanalytical detection systems, and related products; X-ray instruments; analytical tools for electron microscopes, as well as handheld, portable, and mobile X-ray fluorescence spectrometry instruments; atomic force microscopy instrumentation; non-contact nanometer resolution solution topography; and automated X-ray metrology, automated AFM defect-detection, and photomask repair and cleaning equipment. In addition, the company offers advanced optical fluorescence microscopy instruments; products and services to support the multi-omics needs of researchers in translational research, drug, and biomarker discovery; superconducting materials, such as metallic low temperature superconductors; devices and complex tools based on metallic low temperature superconductors; and non-superconducting high technology tools, such as synchrotron and beamline instrumentation. The company was founded in 1960 and is headquartered in Billerica, Massachusetts.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.